TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04440423
Drug: Clotiazepam 5 mg Test Product Coated Tablets
Normalized name: clotiazepam
DrugBank: Clotiazepam (DB01559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Medicinal Product
Study: NCT04440423
Drug: Clotiazepam 5 mg Reference Product Coated Tablets
Normalized name: clotiazepam
DrugBank: Clotiazepam (DB01559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rize (Trademark)
Study: NCT02358356
Drug: octreotate
Normalized name: DOTA-octreotate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
Study: NCT02358356
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: temozolomide 75mg/m2 b.i.d.
Study: NCT02819908
Drug: Imprimis Dropless
Normalized name: Imprime PGG
DrugBank: Odetiglucan (DB17468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-Moxi-Vanc transzonular intravitreal injection
Study: NCT00825253
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00825253
Drug: biphasic human insulin 30
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03493932
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Study: NCT03493932
Drug: BMS-986016
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
Study: NCT00243646
Drug: Lupron
Normalized name: Lupron
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
Study: NCT00243646
Drug: Casodex
Normalized name: Casodex
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
Study: NCT02967757
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
Study: NCT04464226
Drug: Darolutamide (Nubeqa, BAY1841788)
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
Study: NCT04126200
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin will be administered.
Study: NCT04126200
Drug: Feladilimab
Normalized name: Feladilimab
DrugBank: Feladilimab (DB16415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: feladilimab will be administered.
Study: NCT04126200
Drug: Nirogacestat
Normalized name: NIROGACESTAT
DrugBank: Nirogacestat (DB12005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirogacestat will be administered.
Study: NCT04126200
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab will be administered.
Study: NCT04126200
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab will be administered.
Study: NCT02285062
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02285062
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04126200
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered.
Study: NCT04126200
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered.
Study: NCT04126200
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered.
Study: NCT02285062
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02285062
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00928590
Drug: Travoprost/Timolol Maleate Fixed Combination solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00690846
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 mg weekly adalimumab injection.
Study: NCT03914326
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
Study: NCT02896621
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A capsule of amlodipine was taken once daily in the morning for eight weeks.
Study: NCT00948467
Drug: TAK-733
Normalized name: TAK-733
DrugBank: TAK-733 (DB12241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.
Study: NCT00510653
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg by mouth daily for 6 Weeks
Study: NCT01090895
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
Study: NCT00835029
Drug: Clotrimazole varnish
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
Study: NCT00835029
Drug: Clotrimazole troches
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
Study: NCT03375307
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02996058
Drug: Dexmedetomidine 0.35µg/kg /h
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
Study: NCT02996058
Drug: Dexmedetomidine 0.5µg/kg /h
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
Study: NCT02125734
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
Study: NCT02903095
Drug: TD-1439
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01150344
Drug: Malarone (atovaquone + proguanil combination)
Normalized name: atovaquone / proguanil Oral Tablet [Malarone]
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
Study: NCT01150344
Drug: RIAMET (artemether + LUMEFANTRIN combination)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
Study: NCT02631473
Drug: 50mg NANO-efavirenz
Normalized name: efavirenz 50 MG
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OD
Study: NCT02631473
Drug: 400mg NANO-Lopinavir
Normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BID
Study: NCT02631473
Drug: 200mg NANO-Lopinavir
Normalized name: lopinavir 200 MG
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BID
Study: NCT02631473
Drug: 100mg Ritonavir
Normalized name: ritonavir 100 MG
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BID
Study: NCT02631473
Drug: 300mg NANO-Efavirenz
Normalized name: efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG [Symfi]
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OD
Study: NCT02631473
Drug: 600mg Sustiva
Normalized name: efavirenz 600 MG [Sustiva]
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OD
Study: NCT02631473
Drug: 200mg NANO-Efavirenz
Normalized name: efavirenz 200 MG
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OD
Study: NCT02631473
Drug: Kaletra® (lopinavir 400mg/ritonavir 100mg)
DrugBank: Kale (DB14564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT04397770
Drug: apatinib mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
Study: NCT04397770
Drug: Temozolomide Injection
Normalized name: temozolomide Injection
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
Study: NCT00536211
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral tablet, 1000 mg daily for 17 days
Study: NCT03945539
Drug: JNJ-56136379
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.
Study: NCT00436501
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
Study: NCT03798119
Drug: Tenofovir Alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
Study: NCT00692354
Drug: CHR-2797 (tosedostat)
Normalized name: Tosedostat
DrugBank: Tosedostat (DB11781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
Study: NCT00272714
Drug: Afimoxifene (0.057%) in hydroalcoholic gel
Normalized name: Afimoxifene
DrugBank: Afimoxifene (DB04468)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03945539
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.
Study: NCT00991146
Drug: canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: canakinumab
Study: NCT03279289
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg/kg administered intravenous infusion on day 1
Study: NCT03279289
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m2 intravenous infusion
Study: NCT03279289
Drug: folinic acid (dl racemic)
Normalized name: oxolinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 intravenous infusion
Study: NCT03279289
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400 mg/m2 continuous intravenous infusion over 46 hours
Study: NCT00646282
Drug: doxercalciferol
Normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH\>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH \<300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
Study: NCT01444807
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sorafenib 400 mg bid
Study: NCT00668356
Drug: didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
Study: NCT00668356
Drug: didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
Study: NCT01964391
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
Study: NCT01964391
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
Study: NCT03104816
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01964391
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
Study: NCT01964391
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
Study: NCT02504463
Drug: Samidorphan IV
DrugBank: Samidorphan (DB12543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV administration
Study: NCT02504463
Drug: [14c]-Samidorphan sublingual
DrugBank: Samidorphan (DB12543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single sublingual administration containing radiolabel
Study: NCT02504463
Drug: [14c]-Samidorphan oral
DrugBank: Samidorphan (DB12543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral administration containing radiolabel
Study: NCT00825669
Drug: TACE
Normalized name: Tace
DrugBank: Chlorotrianisene (DB00269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
Study: NCT01021696
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol Max. dose: 3g/d
Study: NCT01021696
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
Study: NCT01021696
Drug: Buprenorphine plaster
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5ųg/h, change each 7.day; max. dose: 10ųg/h
Study: NCT01021696
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25mgx1/d; max 300mg/d
Study: NCT01331421
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablet
Study: NCT00156936
Drug: Medisorb naltrexone 380 mg
Normalized name: naltrexone 380 MG
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
Study: NCT00156936
Drug: Oral naltrexone to Medisorb naltrexone 380 mg
Normalized name: naltrexone 380 MG
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
Study: NCT02689986
Drug: Bendamustine, Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bendamustine, Rituximab
Study: NCT04512105
Drug: Pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04512105
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01143389
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
Study: NCT00720447
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00720447
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00720447
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00720447
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02294942
Drug: RANCAD
Normalized name: rancid beef preparation
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-Release RANCAD
Study: NCT02876250
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
Study: NCT03626298
Drug: Adapalene
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
Study: NCT00791076
Drug: Pancreatic Polypeptide (PP)
Normalized name: Heme iron polypeptide
DrugBank: Pancreatic Polypeptide (DB12822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2pmol/kg-1/min-1 PP infused continuously over 72 hours.
Study: NCT02718599
Drug: terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
Study: NCT02125305
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03985293
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
Study: NCT01106469
Drug: JNJ-41443532
Normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg tablet once daily
Study: NCT01106469
Drug: JNJ-41443532
Normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg tablet once daily
Study: NCT01106469
Drug: JNJ-41443532
Normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg once daily (with 250mg tablets)
Study: NCT03790020
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In our study this local anesthetic agent will be applied for postoperative pain relief
Study: NCT01106469
Drug: JNJ-41443532
Normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg tablet once daily
Study: NCT01106469
Drug: JNJ-41443532
Normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg once daily (with 250mg tablets)
Study: NCT01106469
Drug: JNJ-41443532
Normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg once daily (with 250mg tablets)
Study: NCT02183701
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02565134
Drug: PAC-14028 cream 0.1%
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application